Loading patent…
AssigneesInstitut Pasteur, Centre National De La Recherche Scientifique
InventorsMarc Alizon, Pierre Sonigo, Cole Stewart, Oliver Danos, Simon Wain-Hobson
Estimating the term…
The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone λJ19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and peptides obtained therefrom. These peptides correspond to amino acids 239-294, 273-317, 300-327, 334-381, 397-424, and 466-500 of the LAV env. These peptides provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.
A peptide of human immunodeficiency virus type 1 (HIV-1) having the sequence:
A peptide of human immunodeficiency virus type 1 (HIV-1) having the sequence:
An immunogenic composition containing a peptide of human immunodeficiency virus type 1 (HIV-1) having the sequence:
A peptide of HIV-1 having the sequence:
A peptide of HIV-1 having the sequence:
A peptide of HIV-1 having the sequence:
A peptide of HIV-1 having the sequence:
Dependencies are inferred from the claim text.